HIV Infections, Tuberculosis
Conditions
Brief summary
People who are infected with HIV and tuberculosis (TB) need to receive medications that treat both diseases safely and effectively. This study enrolled infants and children infected with HIV and TB and evaluated the safety and tolerance of an antiretroviral (ARV) treatment regimen for HIV that contains raltegravir when administered with a TB treatment regimen that includes rifampicin. Study researchers aimed to determine the most effective dose of raltegravir for infants and children when taken with rifampicin.
Detailed description
People who are infected with HIV are also at risk for becoming infected with TB, particularly in many resource-limited settings, including Sub-Saharan Africa. Rifampicin is a medication commonly used to treat TB. There is a need for HIV treatment regimens that contain newer ARV medications that are well-tolerated and have minimal interactions with rifampicin-containing TB medication regimens. This study enrolled HIV-infected infants and children: who had never taken any ARV medications or who had not received ARVs for at least 30 days prior to study entry; and who were infected with TB and were taking or were starting a TB medication regimen that included rifampicin. The purpose of this study was to evaluate the safety and tolerance of raltegravir-containing ARV regimens to treat HIV when administered with a rifampicin-containing regimen used to treat TB in infants and children. Study researchers also evaluated the pharmacokinetics of the medications (i.e., how medication is absorbed and processed in the body) and determined the most effective dose of raltegravir when administered with a TB regimen that contains rifampicin. During the study, researchers continuously monitored participant data for safety and other factors. Researchers could adjust the dose of raltegravir given to a group of participants prior to enrolling additional participants. At study entry, participants underwent a medical and medication history review, physical examination, medication adherence assessment, blood collection, and urine collection. Participants received chewable raltegravir tablets twice daily, and they also took their TB medications, including rifampicin, and two nucleoside reverse transcriptase inhibitor (NRTI) ARV medications chosen by participants' doctors. This study provided raltegravir to participants; all other medications were prescribed by participants' own doctors. At a study visit at Days 5 to 8, participants remained in the clinic for about 12 hours. They took part in the same study procedures that occurred at the entry visit, but they also had small amounts of blood collected several times throughout the 12 hours to measure the amount of medication in the blood. After the Day 5 to 8 visit, participants began receiving a fourth ARV medication chosen by their doctor, in addition to the other medications. Participants continued receiving raltegravir until they stopped taking their TB medications. They continued to take the third ARV medication and the other two ARV medications for three months after they stopped receiving raltegravir and the TB medications. Additional study visits occurred at Day 14, Weeks 4 and 8, every 4 weeks until the participant stopped receiving raltegravir and their TB medications, and 4 and 12 weeks after stopping raltegravir and the TB medications. These study visits included the same study procedures that occurred at study entry. Participants were expected to participate in the study for a total of about 4 to 9 months. Note that out of the forty (40) participants enrolled only (39) participants received the study treatment (raltegravir). The total enrollment for Cohort 1 was thirteen (13) participants, with only twelve (12) who received raltegravir. Therefore, the results of this submission is based on the 39 participants who received raltegravir.
Interventions
DRUGRaltegravir
Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Weeks to 11 Years
Healthy volunteers
No
Inclusion criteria
* Weight greater than or equal to 3.5 kg at entry * Confirmation of HIV-1 infection was defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum, or plasma. For studies conducted under an Investigational New Drug (IND), all test methods should be Food and Drug Administration (FDA)-approved if available. If FDA-approved methods are not available, test methods should be verified according to good clinical laboratory practice (GCLP) and approved by the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Laboratory Center. More information on this criterion can be found in the protocol. * ARV treatment naïve or did not received ARVs for at least 30 days prior to entry. Note: Participants with prior exposure to ARVs for prevention of mother-to-child transmission (PMTCT) or treatment - regardless of duration - were eligible provided the participant did not received ARVs for at least 30 days prior to entry. The reasons for interruption could include drug toxicity, poor adherence, or treatment failure that preceded enrollment and was not imposed by study staff. ARVs should not be withheld for the purposes of enrollment into the study and against the participant's best interest. * ARV treatment eligible as defined by: 1. Country-specific guidelines OR 2. World Health Organization (WHO) pediatric treatment algorithm (http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684\_eng.pdf?ua=1) * Diagnosis of pulmonary TB or TB adenitis. More information on this criterion can be found in the protocol. * Participant initiated at least a 2-drug TB regimen containing rifampicin, and had tolerated at least 1 week of the TB drug regimen prior to initiation of raltegravir. Note: TB treatment was allowed to be started after being diagnosed by the site investigator. Treatment regimens included isoniazid, pyrazinamide, ethambutol and streptomycin in addition to rifampicin. ART ideally started within 2 weeks of starting TB treatment. A patient who had started therapy for TB elsewhere but was not yet been started on ART was eligible for enrollment provided they did not have greater than 20 weeks of TB therapy. Delay between starting TB treatment and ART was not encouraged, and local or international guidelines should be followed for managing TB and HIV coinfection in infants and children. * Female participant who was of child bearing potential and sexually active agreed to use two reliable methods of contraception, including a medically accepted barrier method of contraception (e.g., female/male condoms, diaphragm or cervical cap with a cream or gel that kills sperm (excluding nonoxydyl-9), intrauterine device \[IUD\], others) together with another reliable form of contraception while on study and for 4 weeks after stopping raltegravir. * Parent, legal guardian, or designated guardian according to country-specific guidelines provided signed informed consent and to have the participant followed at the clinical site
Exclusion criteria
* Greater than or equal to Grade 2 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at screening, which must be within 30 days of entry. Note: Participants were allowed to be re-screened provided that they had at least 4 weeks of TB treatment remaining at the time of entry. * Any greater than or equal to Grade 4 clinical toxicity or laboratory result at screening except fever, chills, fatigue or malaise, unintentional weight loss, and dyspnea or respiratory distress that could be associated with TB * Acute, serious infections other than TB requiring active treatment (e.g., Pneumocystis jirovecii \[previously Pneumocystis carinii\] pneumonia \[PCP\], cryptococcal meningitis, etc.). Infants and children diagnosed with acute bacterial pneumonia at time of diagnosis of TB may be included. Prophylaxis against opportunistic infections was allowed. * Diagnosis of Kwashiorkor (less than 80% expected weight-for-age with the presence of edema and hypoalbuminemia) * Current chemotherapy for active malignancy and history of chemotherapy discontinued within 1 year of entry * Rifampicin therapy of greater than 20 weeks duration immediately prior to enrollment * Known or suspected multidrug resistant (MDR) or extensively drug resistant (XDR) TB, including contact with a documented MDR or XDR TB source case, as these may require longer duration of therapy or non-rifampicin containing regimen. Note: Participants found to have MDR or XDR TB before or during the study were informed of their illness and referred for appropriate care as determined by local guidelines. * Current TB regimen containing rifabutin, macrolides, and any other anti-mycobacterial agents with known interactions with raltegravir * Any clinically significant diseases (other than HIV and TB infection) or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise the outcome of this study * Participant who was pregnant or breastfeeding * Participant who was unlikely to adhere to the study procedures or keep appointments * Participant who was planning to relocate during the study to a non-IMPAACT study site * Participant who was taking any disallowed medications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic (PK) Parameter: Concentration at 12h (C12) | At the study visit between days 5 and 8 of raltegravir initiation; A (0.5) mL of blood sample was drawn at each time point: pre-dose (0), 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post dosing. | Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods (Phoenix WinNonlin 8.1, Certara, Princeton, New Jersey). AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear-log trapezoidal rule. Geometric Means (GM) for C12 were calculated for each cohort. |
| Number of Participants Who Experienced Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks) | Number (Frequency) of Participants who experienced Adverse event(s) of greater than or equal to Grade 3 deemed at least possibly related to raltegravir |
| Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC12h) | At the study visit between days 5 and 8 of raltegravir initiation; A (0.5) mL of blood sample was drawn at each time point: pre-dose (0), 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post dosing. | Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods (Phoenix WinNonlin 8.1, Certara, Princeton, New Jersey). AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear-log trapezoidal rule. Geometric Means (GM) for AUC12h were calculated for each cohort. |
| Number of Participants Who Permanently Discontinued Treatment Due to Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | Measured from the first dose of raltegravir through the participant's last study visit (median of 34 weeks) | Number (Frequency) of participants who permanently discontinued raltegravir study treatment due to an adverse event(s) of greater than or equal to Grade 3, deemed at least possibly related to raltergravir. |
| Number of Participants Who Experienced Death, Grade 4 Life-threatening Adverse Events Deemed at Least Possibly Related to Raltegravir | Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks) | Number (Frequency) of participants who experienced Death, Grade 4 life-threatening adverse events deemed at least possibly related to raltegravir |
| Number of Participants Who Experienced Grade 4 Non-life Threatening Adverse Event(s) Deemed as Probably or Definitely Related to Raltegravir | Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks) | Number (Frequency) of Participants who experienced Grade 4 non-life threatening adverse event(s) deemed as probably or definitely related to raltegravir |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Developed of New Opportunistic Infection(s) (OIs) | Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks) | Number (Frequency) of participants who developed of new opportunistic infection(s) (OIs) |
| Number of Participants Who Failed to Respond Virologically at Week 8, Which Means Having HIV RNA (Copies/mL) Greater Than 400 Copies/mL AND Less Than 1-log10 Drop From Baseline | Measured at Week 8 | Number (Frequency) of Participants who failed to respond virologically at Week 8, which includes HIV RNA (copies/mL) greater than 400 copies/mL AND less than 1-log10 drop from baseline. Please note that the protocol definition of virologic response was: achieving at least a 1-log10 reduction from baseline in HIV-1 RNA (copies/mL) or HIV-1 RNA ≤ 400 copies/mL at week 8. An As-Treated (AT) analysis was carried out, such that participants who permanently discontinued treatment before week 8, without evaluable data were not included in the analyses. |
Countries
South Africa
Participant flow
Recruitment details
Accrual occurred between November 2014 and April 2019 in four (4) sites from South Africa.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
Raltegravir: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily. | 12 |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
Raltegravir: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily. | 14 |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment Participants in this cohort received chewable raltegravir tablets (as a dispersible tablet), starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
Raltegravir: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily. | 13 |
| Total | 39 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Participant never started treatment of raltegravir, was taken off-study. | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Total | Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment |
|---|---|---|---|---|
| Age, Continuous | 3.70 years | 8.55 years | 1.00 years | 3.55 years |
| CD4 Count | 808 cells/mm^3 | 575 cells/mm^3 | 1513 cells/mm^3 | 559 cells/mm^3 |
| CD4 Percent | 16.80 percentage | 21.35 percentage | 16.80 percentage | 15.25 percentage |
| Log10 RNA | 4.97 log10(copies/ml) | 4.55 log10(copies/ml) | 5.13 log10(copies/ml) | 4.91 log10(copies/ml) |
| Race/Ethnicity, Customized Black Non-Hispanic | 38 participants | 14 participants | 13 participants | 11 participants |
| Race/Ethnicity, Customized Hispanic (Regardless of Race) | 1 participants | 0 participants | 0 participants | 1 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 39 Participants | 14 Participants | 13 Participants | 12 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment South Africa | 39 participants | 14 participants | 13 participants | 12 participants |
| Sex: Female, Male Female | 17 Participants | 7 Participants | 5 Participants | 5 Participants |
| Sex: Female, Male Male | 22 Participants | 7 Participants | 8 Participants | 7 Participants |
| Weight | 13.80 kilograms | 21.30 kilograms | 8.03 kilograms | 13.60 kilograms |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 14 | 0 / 13 |
| other Total, other adverse events | 12 / 12 | 14 / 14 | 13 / 13 |
| serious Total, serious adverse events | 8 / 12 | 5 / 14 | 5 / 13 |
Outcome results
Primary
Number of Participants Who Experienced Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir
Number (Frequency) of Participants who experienced Adverse event(s) of greater than or equal to Grade 3 deemed at least possibly related to raltegravir
Time frame: Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks)
Population: Includes all participants who received at least one dose of raltegravir at the final recommended dose for the cohort.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Number of Participants Who Experienced Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | 1 Participants |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Number of Participants Who Experienced Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | 1 Participants |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Number of Participants Who Experienced Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | 0 Participants |
Primary
Number of Participants Who Experienced Death, Grade 4 Life-threatening Adverse Events Deemed at Least Possibly Related to Raltegravir
Number (Frequency) of participants who experienced Death, Grade 4 life-threatening adverse events deemed at least possibly related to raltegravir
Time frame: Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks)
Population: Includes all participants who received at least one dose of raltegravir at the final recommended dose for the cohort.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Number of Participants Who Experienced Death, Grade 4 Life-threatening Adverse Events Deemed at Least Possibly Related to Raltegravir | 0 Participants |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Number of Participants Who Experienced Death, Grade 4 Life-threatening Adverse Events Deemed at Least Possibly Related to Raltegravir | 0 Participants |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Number of Participants Who Experienced Death, Grade 4 Life-threatening Adverse Events Deemed at Least Possibly Related to Raltegravir | 0 Participants |
Primary
Number of Participants Who Experienced Grade 4 Non-life Threatening Adverse Event(s) Deemed as Probably or Definitely Related to Raltegravir
Number (Frequency) of Participants who experienced Grade 4 non-life threatening adverse event(s) deemed as probably or definitely related to raltegravir
Time frame: Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks)
Population: Includes all participants who received at least one dose of raltegravir at the final recommended dose for the cohort.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Number of Participants Who Experienced Grade 4 Non-life Threatening Adverse Event(s) Deemed as Probably or Definitely Related to Raltegravir | 0 Participants |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Number of Participants Who Experienced Grade 4 Non-life Threatening Adverse Event(s) Deemed as Probably or Definitely Related to Raltegravir | 0 Participants |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Number of Participants Who Experienced Grade 4 Non-life Threatening Adverse Event(s) Deemed as Probably or Definitely Related to Raltegravir | 0 Participants |
Primary
Number of Participants Who Permanently Discontinued Treatment Due to Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir
Number (Frequency) of participants who permanently discontinued raltegravir study treatment due to an adverse event(s) of greater than or equal to Grade 3, deemed at least possibly related to raltergravir.
Time frame: Measured from the first dose of raltegravir through the participant's last study visit (median of 34 weeks)
Population: Includes all participants who received at least one dose of raltegravir at the final recommended dose for the cohort.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Number of Participants Who Permanently Discontinued Treatment Due to Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | 0 Participants |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Number of Participants Who Permanently Discontinued Treatment Due to Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | 1 Participants |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Number of Participants Who Permanently Discontinued Treatment Due to Adverse Event(s) of Greater Than or Equal to Grade 3 Deemed at Least Possibly Related to Raltegravir | 0 Participants |
Primary
Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC12h)
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods (Phoenix WinNonlin 8.1, Certara, Princeton, New Jersey). AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear-log trapezoidal rule. Geometric Means (GM) for AUC12h were calculated for each cohort.
Time frame: At the study visit between days 5 and 8 of raltegravir initiation; A (0.5) mL of blood sample was drawn at each time point: pre-dose (0), 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post dosing.
Population: Participants with intensive pharmacokinetic (PK) results at the final recommended dose in each Age Cohort
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC12h) | 12.8 h*mg/L |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC12h) | 17.2 h*mg/L |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC12h) | 14.6 h*mg/L |
Primary
Pharmacokinetic (PK) Parameter: Concentration at 12h (C12)
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods (Phoenix WinNonlin 8.1, Certara, Princeton, New Jersey). AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear-log trapezoidal rule. Geometric Means (GM) for C12 were calculated for each cohort.
Time frame: At the study visit between days 5 and 8 of raltegravir initiation; A (0.5) mL of blood sample was drawn at each time point: pre-dose (0), 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post dosing.
Population: Participants with intensive pharmacokinetic (PK) results at the final recommended dose in each Age Cohort
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Pharmacokinetic (PK) Parameter: Concentration at 12h (C12) | 101.8 ng/mL |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Pharmacokinetic (PK) Parameter: Concentration at 12h (C12) | 101.2 ng/mL |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Pharmacokinetic (PK) Parameter: Concentration at 12h (C12) | 47.3 ng/mL |
Secondary
Number of Participants Who Developed of New Opportunistic Infection(s) (OIs)
Number (Frequency) of participants who developed of new opportunistic infection(s) (OIs)
Time frame: Measured from the first dose of raltegravir through a participant's last study visit (median of 34 weeks)
Population: Includes all participants who received at least one dose of raltegravir at the final recommended dose for the cohort.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Number of Participants Who Developed of New Opportunistic Infection(s) (OIs) | 1 Participants |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Number of Participants Who Developed of New Opportunistic Infection(s) (OIs) | 0 Participants |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Number of Participants Who Developed of New Opportunistic Infection(s) (OIs) | 1 Participants |
Secondary
Number of Participants Who Failed to Respond Virologically at Week 8, Which Means Having HIV RNA (Copies/mL) Greater Than 400 Copies/mL AND Less Than 1-log10 Drop From Baseline
Number (Frequency) of Participants who failed to respond virologically at Week 8, which includes HIV RNA (copies/mL) greater than 400 copies/mL AND less than 1-log10 drop from baseline. Please note that the protocol definition of virologic response was: achieving at least a 1-log10 reduction from baseline in HIV-1 RNA (copies/mL) or HIV-1 RNA ≤ 400 copies/mL at week 8. An As-Treated (AT) analysis was carried out, such that participants who permanently discontinued treatment before week 8, without evaluable data were not included in the analyses.
Time frame: Measured at Week 8
Population: Includes all participants who received at least one dose of raltegravir at the final recommended dose for the cohort. Please note that an as-Treated (AT) analysis was carried out, such that participants who permanently discontinued treatment before week 8, without evaluable data were not included in the analyses.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment | Number of Participants Who Failed to Respond Virologically at Week 8, Which Means Having HIV RNA (Copies/mL) Greater Than 400 Copies/mL AND Less Than 1-log10 Drop From Baseline | 1 Participants |
| Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment | Number of Participants Who Failed to Respond Virologically at Week 8, Which Means Having HIV RNA (Copies/mL) Greater Than 400 Copies/mL AND Less Than 1-log10 Drop From Baseline | 1 Participants |
| Cohort 3: : ≥ 4 Weeks to < 2 Years of Age on TB Treatment | Number of Participants Who Failed to Respond Virologically at Week 8, Which Means Having HIV RNA (Copies/mL) Greater Than 400 Copies/mL AND Less Than 1-log10 Drop From Baseline | 1 Participants |